Bolt Biotherapeutics, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 20 million compared to USD 27.16 million a year ago. Basic loss per share from continuing operations was USD 0.53 compared to USD 0.73 a year ago. Diluted loss per share from continuing operations was USD 0.53 compared to USD 0.73 a year ago.

For the full year, the company reported net loss was USD 88.1 million compared to USD 98.59 million a year ago. Basic loss per share from continuing operations was USD 2.36 compared to USD 2.97 a year ago. Diluted loss per share from continuing operations was USD 2.36 compared to USD 2.97 a year ago.